肌肉减少症对复杂主动脉瘤修复术后死亡率和脊髓缺血的影响:系统评价与Meta分析
该系统评价与Meta分析检索截至2022年6月15日的英文文献,纳入4项回顾性研究共1092例患者(40.0%存在肌肉减少症),评估肌肉减少症与复杂主动脉瘤开放或腔内修复术后30天死亡率、中期死亡率及30天脊髓缺血的关系。结果示30天死亡率两组相似(低确定性),肌肉减少症组中期死亡率(25% vs 13%,极低确定性)和脊髓缺血发生率(19% vs 7%,极低确定性)显著更高,但异质性较高。
要点
- 肌肉减少症组与非肌肉减少症组30天死亡率相似(6% vs 5%,OR 0.30,p=.94,I²=0%)。
- 肌肉减少症组中期死亡率显著更高(25% vs 13%,p<.001,I²=88.32%,极低确定性)。
- 肌肉减少症组30天脊髓缺血显著更高(19% vs 7%,I²=82.4%,极低确定性)。
核心结论
- 早期死亡率似乎不受肌肉减少症影响,但肌肉减少症可能与更高的围手术期脊髓缺血和中期死亡率相关。
研究设计与样本
- 系统评价与Meta分析,遵循PRISMA指南并在PROSPERO注册(CRD42022338079)。
- 检索Ovid平台Medline、EMBASE和CENTRAL截至2022年6月15日的英文文献。
- 纳入2000至2022年、样本量≥5例、报告肌肉减少症相关30天死亡率和脊髓缺血及胸腹主动脉瘤修复术后中期死亡率的观察性研究。
- 共纳入4项回顾性研究,1092例患者,其中40.0%存在肌肉减少症。
- 采用ROBINS-I工具评估偏倚风险,GRADE评估证据质量。
主要发现
- 30天死亡率:肌肉减少症组6%(95%CI 1-11) vs 非肌肉减少症组5%(95%CI 1-9),OR 0.30(95%CI -0.21-0.81),p=.94,I²=0%,低确定性,两组相似。
- 中期死亡率:肌肉减少症组25%(95%CI 0.19-0.31) vs 非肌肉减少症组13%(95%CI -0.03-0.29),OR 1.11(原文写作1.11 OR 0.95,95%CI -0.21-2.44),p<.001,I²=88.32%,极低确定性,肌肉减少症组显著更高。
- 30天脊髓缺血:肌肉减少症组19%(95%CI 4-34) vs 非肌肉减少症组7%(95%CI 5-20),OR 1.80(95%CI -0.17-3.78),I²=82.4%,极低确定性,肌肉减少症组显著更高。
- 两组动脉瘤类型分布相等。
临床怎么用
- 原文未据此给出推荐。
局限性
- 纳入研究均为回顾性研究。
- 30天死亡率证据确定性低。
- 中期死亡率和脊髓缺血证据确定性极低。
- 中期死亡率分析异质性I²=88.32%。
- 脊髓缺血分析异质性I²=82.4%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Sarcopenia has been related to higher mortality rates after abdominal aortic aneurysm repair. This analysis aimed to assess sarcopenia related mortality and spinal cord ischaemia (SCI) at 30 days, and mortality during the available follow up, in patients with complex aortic aneurysms, managed with open or endovascular interventions. DATA SOURCES: A search of the English literature, via Ovid, using Medline, EMBASE, and CENTRAL up to 15 June 2022 was done. REVIEW METHODS: This meta-analysis was conducted according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) guidelines and preregistered in PROSPERO (CRD42022338079). Observational studies (2000 - 2022), with five or more patients, reporting on sarcopenia related mortality and SCI at 30 days, and midterm mortality after thoraco-abdominal aneurysm repair (open or endovascular), were eligible. The ROBINS-I tool (Risk Of Bias In Non-Randomised Studies of Interventions) was used for risk of bias, and GRADE (Grading of Recommendations, Assessment, Development and Evaluation) for the assessment of evidence quality. The primary outcome was 30 day and midterm mortality, and the secondary outcome was SCI at 30 days, in sarcopenic and non-sarcopenic patients. The outcomes were summarised as odds ratio (OR) with 95% confidence intervals (CIs). RESULTS: Four retrospective studies (1 092 patients; 40.0% sarcopenic) were included. Thirty day mortality was similar, with low certainty between groups (6% [95% CI 1 - 11] in sarcopenic vs. 5% [95% CI 1 - 9] non-sarcopenic patients [OR 0.30, 95% CI -0.21 - 0.81; p = .94, Ι2 = 0%). The estimated midterm mortality was statistically significantly higher (very low certainty) in sarcopenic patients (25% [95% CI 0.19 - 0.31] vs. 13% [95% CI -0.03 - 0.29] in non-sarcopenic patients (1.11 OR 0.95, 95% CI -0.21 - 2.44; p < .001, Ι2 = 88.32%). SCI was significantly higher (very low certainty) in sarcopenic patients (19%, 95% CI 4 - 34) vs. 7% (95% CI 5 - 20) in non-sarcopenic patients (OR 1.80, 95% CI -0.17 - 3.78; Ι2 = 82.4%), despite an equal distribution of aneurysm type between the groups. CONCLUSION: Early mortality does not appear to be affected by sarcopenia in patients treated for thoraco-abdominal aneurysms. However, sarcopenia may be associated with higher peri-operative SCI and midterm mortality rates.
引用
- Nana P, Spanos K, Brotis A, et al. Effect of Sarcopenia on Mortality and Spinal Cord Ischaemia After Complex Aortic Aneurysm Repair: Systematic Review and Meta-Analysis. Eur J Vasc Endovasc Surg. 2023. PMID: 36657704. doi:10.1016/j.ejvs.2023.01.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。